{
    "id": 5410,
    "name": "pulmonary neuroendocrine tumor",
    "source": "DOID",
    "definition": null,
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:5410",
    "evidence": [
        {
            "id": 11468,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, M7824 saturated peripheral CD274 (PD-L1) and sequestered plasma TGFbeta 1/2/3, resulted in prolonged stable disease in a bronchopulmonary carcinoid tumor patient (PMID: 29298798; NCT02517398).",
            "molecularProfile": {
                "id": 28058,
                "profileName": "CD274 pos TGFB1 pos"
            },
            "therapy": {
                "id": 5860,
                "therapyName": "M7824",
                "synonyms": null
            },
            "indication": {
                "id": 5410,
                "name": "pulmonary neuroendocrine tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9078,
                    "pubMedId": null,
                    "title": "Preliminary results from a phase 1 trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-?, in advanced solid tumors.",
                    "url": "http://abstracts.asco.org/199/AbstView_199_187226.html"
                },
                {
                    "id": 11321,
                    "pubMedId": 29298798,
                    "title": "Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGF\u03b2, in Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29298798"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT02834013",
            "title": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors",
            "phase": "Phase 0",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03278379",
            "title": "Avelumab in G2-3 NET (NET-002)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3144,
                    "therapyName": "Avelumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03278405",
            "title": "Avelumab in G3 NEC (NET-001)",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3144,
                    "therapyName": "Avelumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03325816",
            "title": "Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03411915",
            "title": "A Study of XmAb18087 in Subjects With NET and GIST",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7309,
                    "therapyName": "XmAb18087",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03420521",
            "title": "Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03670030",
            "title": "A Study to Test the Effectiveness of ABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3380,
                    "therapyName": "Nab-Rapamycin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03879694",
            "title": "Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8087,
                    "therapyName": "Octreotide + Sargramostim + SurVaxM",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04123262",
            "title": "Tamoxifen for Well Differentiated Neurodendocrine Tumors and Hormone Receptor Positive Expression",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1456,
                    "therapyName": "Tamoxifen",
                    "synonyms": null
                }
            ]
        }
    ]
}